



XTL Biopharmaceuticals to Present at the Arch Investment Conference

Valley Cottage, New York, September 5, 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Arch Investment Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of neuropathic pain. Mr. Bentsur's presentation will take place, tomorrow, Thursday, September 6, 2007 at 11:30 pm Eastern Daylight Time, at the Warwick Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at:
<http://www.informedinvestors.com/VC/ClientPage.asp?ID=45356>. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225